• PF-562271 HCl: Benchmark FAK/Pyk2 Inhibitor for Cancer Resea

  2026-06-16

  PF-562271 HCl is a potent, selective FAK/Pyk2 inhibitor that enables precise modulation of focal adhesion kinase signaling in cancer research. It demonstrates nanomolar inhibition of FAK and dose-dependent suppression of tumor growth in preclinical models, supporting its utility for dissecting oncogenic pathways and evaluating anti-metastatic strategies.

• Deuterated Tetrazole CYP51 Inhibitors for Resistant Fungal I

  2026-06-16

  The reference study introduces a deuterated tetrazole CYP51 inhibitor (V23) with broad-spectrum, in vivo effective antifungal activity and improved selectivity over human CYPs. This innovation demonstrates significant advances for overcoming resistance and minimizing toxicity in the treatment of invasive fungal infections.

• 3D Electrophysiology of Cardiac Organoids with Shell MEAs

  2026-06-15

  Choi et al. introduce programmable shell microelectrode arrays (MEAs) that enable high-resolution, 3D spatiotemporal mapping of electrical activity in human cardiac organoids. This innovation overcomes limitations of conventional 2D platforms, supporting advanced disease modeling and pharmacological screening, including with hERG potassium channel blockers.

• Energy Deficiency Drives ATG4B Nuclear Translocation in AML

  2026-06-15

  This study uncovers how cellular energy deficiency induces nuclear translocation of ATG4B, impairing PRMT1-mediated DNA repair and accelerating leukemia progression. The findings establish a mechanistic link between metabolism and genomic instability, highlighting ATG4B as a promising therapeutic target in acute myeloid leukemia.

• MOB1A/B Loss Drives Intestinal Degeneration via BMP/TGF-β Ac

  2026-06-14

  This study reveals that depletion of MOB1A/B in intestinal epithelial cells leads to degeneration by suppressing Wnt signaling and enhancing BMP/TGF-β pathways. Partial restoration of secretory cell differentiation is achieved using BMP and TGF-β pathway inhibitors, highlighting complex regulatory crosstalk and providing a mechanistic basis for targeted pathway modulation in intestinal homeostasis research.

• Real-World Immunoassay Solutions with c-Myc tag Peptide (A60

  2026-06-13

  This scenario-driven guide addresses common immunoassay and cell analysis challenges with evidence-based strategies using the c-Myc tag Peptide (SKU A6003). Explore how this synthetic peptide optimizes anti-c-Myc antibody binding inhibition and enhances reproducibility in cell viability and proliferation assays, supported by literature and validated protocols.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-06-12

  The reference study identifies a new class of nanomolar allosteric inhibitors targeting pyruvate dehydrogenase kinase 4 (PDK4), with strong in vitro and in vivo efficacy in models of metabolic disease, allergy, and cancer. This work advances the field by providing a structurally distinct, orally active scaffold for selective PDK4 inhibition and highlights its translational relevance for metabolic modulation.

• Dual-Metric In Vitro Drug Response Evaluation in Cancer Rese

  2026-06-12

  Schwartz's dissertation introduces a dual-metric framework distinguishing proliferative arrest from cell death in in vitro cancer drug assays. This approach provides clearer mechanistic insights, enabling more precise interpretation of DNA topoisomerase II inhibitor studies and informing assay optimization for future research.

• IEM 1460: Unraveling AMPA Receptor Blockade in Neurotoxicity

  2026-06-11

  Discover how IEM 1460, a selective AMPA receptor blocker, is revolutionizing neurotoxicity and neuroprotection research. This article explores the molecular mechanism, assay design, and translational insights for advanced neuroscience workflows.

• hiPSC-Derived Sensory Neurons Enable HSV-1 Latency Modeling

  2026-06-11

  This study establishes a robust, scalable protocol for differentiating human inducible pluripotent stem cells into functional sensory neurons that support latent infection and reactivation of herpes simplex virus 1 (HSV-1). The model overcomes longstanding barriers to studying HSV-1 latency in human neurons, enabling mechanistic and therapeutic investigations previously limited to animal systems.

• Bufalin: A Cardiotonics Benchmark for Cancer Research Workfl

  2026-06-10

  Bufalin, a cardiotonic steroid from APExBIO, is redefining experimental cancer research by acting as a potent apoptosis inducer and molecular glue degrader. This article unpacks best-in-class protocols and troubleshooting strategies for leveraging Bufalin in triple-negative breast cancer and hepatocellular carcinoma models.

• DOTAP-Mediated Nucleic Acid Delivery: Mechanisms and Immune

  2026-06-10

  Explore how 1,2-Dioleoyl-3-trimethylammonium-propane chloride (DOTAP) revolutionizes nucleic acid delivery and immune modulation. This article uniquely bridges cutting-edge metabolic reprogramming insights with practical guidance for advanced gene delivery and functional genomics workflows.

• Reversine and Aurora Kinase Inhibition: Translational Insigh

  2026-06-09

  Explore how Reversine, a potent Aurora kinase inhibitor from APExBIO, enables translational researchers to dissect mitotic checkpoint dynamics and drive impactful cancer research. This article bridges mechanistic understanding and strategic guidance, integrating new regulatory insights from the p31comet-Plk1 axis and offering actionable protocols for experimental success.

• AG-120 (Ivosidenib): Precision Workflows for AML Mutant IDH1

  2026-06-09

  AG-120 (Ivosidenib) empowers researchers to achieve robust 2-hydroxyglutarate reduction and restore myeloid differentiation in IDH1-mutant AML models. This article delivers actionable protocols, troubleshooting strategies, and translates the latest metabolic rewiring insights into practical, high-impact research workflows.

• Optimizing Cancer Assays: Sunitinib (SKU B1045) for Reliable

  2026-06-08

  This article explores real-world laboratory challenges in apoptosis, viability, and cytotoxicity assays, highlighting how Sunitinib (SKU B1045) from APExBIO delivers consistent, data-backed solutions for robust RTK inhibition. Scenario-driven Q&As address protocol optimization, data interpretation, and product selection, equipping cancer researchers with validated best practices.

15659 records 1/1044 page Next 12345 下5页 Last page